Phase III, randomized, placebo-controlled study of once-daily oral zibotentan (ZD4054) in patients with non-metastatic castration-resistant prostate cancer

K. Miller,Judd W. Moul,Martin Gleave,Karim Fizazi,Joel B. Nelson,Thomas Morris,Faith Nathan,Stuart McIntosh,Kristine Pemberton,Celestia S. Higano

Phase III, randomized, placebo-controlled study of once-daily oral zibotentan (ZD4054) in patients with non-metastatic castration-resistant prostate cancer

2013

K. Miller
Judd W. Moul
Martin Gleave
Karim Fizazi
Joel B. Nelson
Thomas Morris
Faith Nathan
Stuart McIntosh
Kristine Pemberton
Celestia S. Higano

Phase III, randomized, placebo-controlled study of once-daily oral zibotentan (ZD4054) in patients with non-metastatic castration-resistant prostate cancer

Keywords:

Urology
Benign prostatic hyperplasia (BPH)
Prostatectomy
Zibotentan
Prostate cancer
Prostate-specific antigen
Prostatitis
Placebo-controlled study
PCA3
Medicine
Interim analysis
Placebo
Standard treatment
Hazard ratio

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations